Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Current Assets (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Current Assets data on record, last reported at $549.7 million in Q4 2025.

  • For Q4 2025, Current Assets rose 39.94% year-over-year to $549.7 million; the TTM value through Dec 2025 reached $549.7 million, up 39.94%, while the annual FY2025 figure was $549.7 million, 39.94% up from the prior year.
  • Current Assets reached $549.7 million in Q4 2025 per MIRM's latest filing, up from $530.6 million in the prior quarter.
  • Across five years, Current Assets topped out at $549.7 million in Q4 2025 and bottomed at $147.2 million in Q2 2022.
  • Average Current Assets over 5 years is $316.5 million, with a median of $375.7 million recorded in 2023.
  • Peak YoY movement for Current Assets: tumbled 35.52% in 2022, then soared 160.46% in 2023.
  • A 5-year view of Current Assets shows it stood at $166.6 million in 2021, then increased by 14.19% to $190.2 million in 2022, then surged by 103.73% to $387.5 million in 2023, then rose by 1.35% to $392.8 million in 2024, then skyrocketed by 39.94% to $549.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $549.7 million in Q4 2025, $530.6 million in Q3 2025, and $453.4 million in Q2 2025.